1. Home
  2. SAR vs ACIU Comparison

SAR vs ACIU Comparison

Compare SAR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAR
  • ACIU
  • Stock Information
  • Founded
  • SAR 2007
  • ACIU 2003
  • Country
  • SAR United States
  • ACIU Switzerland
  • Employees
  • SAR N/A
  • ACIU N/A
  • Industry
  • SAR Investment Managers
  • ACIU Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAR Finance
  • ACIU Health Care
  • Exchange
  • SAR Nasdaq
  • ACIU Nasdaq
  • Market Cap
  • SAR 331.7M
  • ACIU 305.7M
  • IPO Year
  • SAR 2007
  • ACIU 2016
  • Fundamental
  • Price
  • SAR $24.41
  • ACIU $3.27
  • Analyst Decision
  • SAR Buy
  • ACIU Strong Buy
  • Analyst Count
  • SAR 4
  • ACIU 2
  • Target Price
  • SAR $25.42
  • ACIU $12.00
  • AVG Volume (30 Days)
  • SAR 47.5K
  • ACIU 86.5K
  • Earning Date
  • SAR 10-08-2024
  • ACIU 11-05-2024
  • Dividend Yield
  • SAR 12.11%
  • ACIU N/A
  • EPS Growth
  • SAR N/A
  • ACIU N/A
  • EPS
  • SAR 1.57
  • ACIU N/A
  • Revenue
  • SAR $155,255,243.00
  • ACIU $48,505,404.00
  • Revenue This Year
  • SAR $5.75
  • ACIU N/A
  • Revenue Next Year
  • SAR N/A
  • ACIU $938.44
  • P/E Ratio
  • SAR $15.56
  • ACIU N/A
  • Revenue Growth
  • SAR 20.62
  • ACIU 4097200.00
  • 52 Week Low
  • SAR $21.56
  • ACIU $2.25
  • 52 Week High
  • SAR $27.00
  • ACIU $5.14
  • Technical
  • Relative Strength Index (RSI)
  • SAR 62.37
  • ACIU 54.36
  • Support Level
  • SAR $23.16
  • ACIU $2.80
  • Resistance Level
  • SAR $24.15
  • ACIU $3.12
  • Average True Range (ATR)
  • SAR 0.34
  • ACIU 0.17
  • MACD
  • SAR -0.01
  • ACIU 0.03
  • Stochastic Oscillator
  • SAR 89.57
  • ACIU 97.92

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: